CLINICAL ROLE -
Improving Care for Patients with Kidney Disease Who Are Pregnant, Undergoing Dialysis
Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.
Watch
Novel Biomarkers, Diagnostic Approaches for Subtyping Bone Turnover, Improving Patient Outcomes
Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.
New Weight Loss Drugs May Have Cardiorenal Benefits for Patients with Kidney Disease
Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.
Read More
Common Medications for Diabetic Kidney Disease May Be Linked to Increased Risk of Hyperkalemia
Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.
Exercise May Reduce Mortality Among Patients on Dialysis, But Low Compliance Makes Concrete Recommendations Difficult
Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.
Navigating Medication Challenges in Kidney Disease, Updating Prior Drug Dosing Consensus
Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.
Various Cancer Types, Drugs May Cause Thrombotic Microangiopathy, Impact Kidney Health
Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.
Serotypes 3, 19A Most Common for Pneumococcal Community-Acquired Pneumonia
Pneumococcal serotype 3 was prevalent regardless of vaccination status, with the most common cases being in those with chronic lung disease.
Understanding the Continuum of Pharmacist Prescribing
It is crucial to continue to evolve from dependent prescribing to an independent model, and address barriers with opportunities for change.
Expert: ‘We Can Do Better’ to Assess Risk of Acute Kidney Injury
Nephrotoxic care can be improved with better risk score assessment and provider education.
Older Adults Remain at High Risk for Hospitalization or Death if Infected with COVID-19
Oldest adults should be prioritized for vaccinations as they remain high risk for severe conditions if infected.
Machine Learning Models Can Improve Efforts to Offer Dynamic, Precise Kidney Care
Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.
Pharmacists Assist with Family Planning in Warfarin Patients
In most patients who are pregnant or may become pregnant, warfarin is contraindicated due to increased risk of adverse fetal outcomes.
Pharmacy Focus: AMCP Nexus 2023 - Recap on Biosimilar Updates
On this month's episode, Pharmacy Times covers the Academy of Managed Care Pharmacy Nexus 2023 conference, highlighting the updates on biosimilars.
Listen
Inflation Reduction Act Could Cause Delay in New Oncology Treatments Under Medicare Negotiations
In an article by The New England Journal of Medicine, the authors discuss how drug companies could delay the approval of new oncology drugs under the IRA, delaying patient care.
Precision Medicine, Biomarkers, Advancements in Chronic Kidney Disease Treatment
Coca notes the importance of precision medicine in CKD risk assessment and describes the potential impact multiple therapies can have on future CKD prediction and treatment in the future.
Non-Coding RNA, Other Therapeutics Can Impact Acute Kidney Injury Treatment, Recovery
The principal investigator of the Centre for Cardiovascular Science at the University of Edinburgh notes that enhancing endogenous repair can lead to a breakthrough in AKI treatment.
Hyperkalemia Recurrence in Patients With CKD Contributes to Increased Health Care Resource Utilization, Cost
The increased costs for patients with recurrent hyperkalemia were driven by the increased inpatient medical cost of additional time spent in the hospital following recurrence.
Patients With CKD, Hyperkalemia Have Higher Rates of Major Adverse Cardiovascular Events
An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.
FDA Approves Vonoprazan for Erosive GERD
The approval marks the first major innovation in the United States for the treatment of erosive GERD in over 30 years.
5 Ways Pharmacies Can Use Texting to Boost Patient Engagement
Texting with patients can help to improve pharmacy processes while creating better user experiences.
Building a Path to Cure for Patients With NSCLC Who Have Never Smoked
How patients acquire NSCLC plays a role in health outcomes, with never-smoker patients having genetically different disease than the same disease in smokers.
Implantable Artificial Kidneys, An Alternative Treatment Method for Kidney Disease
Outside of dialysis and transplantations, implantable artificial kidneys present an additional option for treating kidney disease, according to an expert.
Ending the Financial Toxicity of Heart Disease
How pharmacy teams can remove cost barriers to cardiac care.
Pharmacists Address Social Determinants of Health in HIV
Paul Rainville, PharmD, CSP, AAHIVP, a clinical pharmacist and subject matter expert with Shields Health Solutions, discussed the current state of HIV in the United States
Nanotherapy Offers Innovative Approaches to Diabetic Retinopathy
Preclinical studies and clinical trials have shown that both corticosteroids and VEGF inhibitors can be delivered as nanoparticles.
5 Key Sessions, Interviews at ASN 2023 Kidney Week Annual Meeting
Pharmacy Times will be at the American Society for Nephrology’s (ASN) 2023 Kidney Week Annual Meeting in Philadelphia, Pennsylvania, from November 2 to 5.
Clinical Overview: Etrasimod for Ulcerative Colitis
Etrasimod is an advanced synthetic compound classified as a selective modulator of Sphingosine 1-phosphate (S1P) receptors, specifically targeting S1P1, S1P4, and S1P5 receptors .
Asymptomatic Carriers of C diff Have 24-times Greater Risk for Developing C diff Compared to Noncarriers
Routine screenings for C diff on admission to the hospital could possibly prevent C diff transmission in the hospital setting.
FDA Approves Interchangeable Biosimilar Ustekinumab-auub for Inflammatory Diseases
The biosimilar, now legally available at the pharmacy level, demonstrated similar safety, purity, and potency to the reference product.
